Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Trends Cancer. 2022 Jul;8(7):556-569. doi: 10.1016/j.trecan.2022.03.004. Epub 2022 May 5.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its highly reactive inflammatory desmoplastic stroma with evidence of an extensive tumor stromal interaction largely mediated by inflammatory factors. KRAS mutation and inflammatory signaling promote protumorigenic events, including metabolic reprogramming with several inter-regulatory crosstalks to fulfill the high demand of energy and regulate oxidative stress for tumor growth and progression. Notably, the more aggressive molecular subtype of PDAC enhances influx of glycolytic intermediates. This review focuses on the interactive role of inflammatory signaling and metabolic reprogramming with emerging evidence of crosstalk, which supports the development, progression, and therapeutic resistance of PDAC. Understanding the emerging crosstalk between inflammation and metabolic adaptations may identify potential targets and develop novel therapeutic approaches for PDAC.
胰腺导管腺癌 (PDAC) 的特征是其高度活跃的炎症性纤维母细胞性基质,有大量证据表明广泛的肿瘤基质相互作用主要由炎症因子介导。KRAS 突变和炎症信号促进促肿瘤发生事件,包括代谢重编程,以及几个相互调节的交叉对话,以满足能量的高需求,并调节氧化应激以促进肿瘤生长和进展。值得注意的是,PDAC 侵袭性更强的分子亚型增强了糖酵解中间产物的流入。本综述重点关注炎症信号和代谢重编程的相互作用作用以及新兴的串扰证据,这支持了 PDAC 的发展、进展和治疗耐药性。了解炎症和代谢适应之间新兴的串扰可能为 PDAC 确定潜在的靶点并开发新的治疗方法。